
Andrea Boutros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4950648/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human Reproduction, 2022, 37, 954-968. | 0.9 | 41 |
| 2 | Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. Cancers, 2022, 14, 1388. | 3.7 | 22 |
| 3 | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer, 2021, 21, 425. | 2.6 | 16 |
| 4 | Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. Frontiers in Oncology, 2021, 11, 739006. | 2.8 | 12 |
| 5 | How to Protect Ovarian Function before and during Chemotherapy?. Journal of Clinical Medicine, 2021, 10, 4192. | 2.4 | 11 |
| 6 | Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. European Journal of Cancer, 2021, 159, 154-166. | 2.8 | 19 |
| 7 | New Melanoma Staging: Prognostic Factors. Updates in Surgery Series, 2021, , 47-53. | 0.1 | 0 |
| 8 | Current State of Target Treatment in BRAF Mutated Melanoma. Frontiers in Molecular Biosciences, 2020, 7, 154. | 3.5 | 82 |
| 9 | Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. Cancer Immunology, Immunotherapy, 2020, 69, 653-662. | 4.2 | 16 |
| 10 | Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. Expert Review of Anticancer Therapy, 2020, 20, 403-413. | 2.4 | 2 |
| 11 | The adjuvant treatment revolution for high-risk melanoma patients. Seminars in Cancer Biology, 2019, 59, 283-289. | 9.6 | 40 |
| 12 | Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Seminars in Cancer Biology, 2019, 59, 290-297. | 9.6 | 78 |